In the past week, NRXP stock has gone down by -18.92%, with a monthly decline of -29.82% and a quarterly plunge of -49.58%. The volatility ratio for the week is 8.34%, and the volatility levels for the last 30 days are 6.74% for NRX Pharmaceuticals Inc The simple moving average for the past 20 days is -22.47% for NRXP’s stock, with a -63.34% simple moving average for the past 200 days.
Is It Worth Investing in NRX Pharmaceuticals Inc (NASDAQ: NRXP) Right Now?
Company’s 36-month beta value is 1.24.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NRXP is 7.90M, and currently, short sellers hold a 6.74% ratio of that floaft. The average trading volume of NRXP on October 16, 2024 was 80.00K shares.
NRXP) stock’s latest price update
NRX Pharmaceuticals Inc (NASDAQ: NRXP)’s stock price has gone decline by -9.09 in comparison to its previous close of 1.32, however, the company has experienced a -18.92% decrease in its stock price over the last five trading days. prnewswire.com reported 2024-10-03 that Clinic to serve as the prototype for HOPE’s network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company’s standard of care across the HOPE network Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI, Oct. 3, 2024 /PRNewswire/ — HOPE Therapeutics, Inc., (“HOPE,” the “Company”), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO).
NRXP Trading at -30.09% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.64% of loss for the given period.
Volatility was left at 6.74%, however, over the last 30 days, the volatility rate increased by 8.34%, as shares sank -26.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.30% lower at present.
During the last 5 trading sessions, NRXP fell by -18.92%, which changed the moving average for the period of 200-days by -74.14% in comparison to the 20-day moving average, which settled at $1.5477. In addition, NRX Pharmaceuticals Inc saw -73.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -2907.75 for the present operating margin
- 0.38 for the gross margin
The net margin for NRX Pharmaceuticals Inc stands at -3102.38. The total capital return value is set at 1.26. Equity return is now at value -682.61, with -197.97 for asset returns.
Based on NRX Pharmaceuticals Inc (NRXP), the company’s capital structure generated -0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -1.74. The debt to equity ratio resting at -0.47. The interest coverage ratio of the stock is -66.46.
Currently, EBITDA for the company is -27.58 million with net debt to EBITDA at -0.29. When we switch over and look at the enterprise to sales, we see a ratio of 2449.43. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
In a nutshell, NRX Pharmaceuticals Inc (NRXP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
